{"DataElement":{"publicId":"3436357","version":"1","preferredName":"Non Muscle Invasive Bladder Cancer Treatment Type","preferredDefinition":"Text term that describes the type of treatment given for the non-muscle invasive bladder tumor.","longName":"3288506v1.0:3436269v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3288506","version":"1","preferredName":"Patient Medical History Non Muscle Invasive Bladder Cancer","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._an account of all medical events and problems a person has experienced._An operation in which a term denies or inverts the meaning of another term or construction._Muscle; one of the contractile organs of the body._Marked by a tendency to spread especially into healthy tissue._A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","longName":"2466333v1.0:3288504v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2466333","version":"1","preferredName":"Patient Personal Medical History","preferredDefinition":"A person who requires medical care.:an account of all medical events and problems a person has experienced.","longName":"C16960:C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1015B737-0744-2BBB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-28","endDate":null,"createdBy":"PWEST","dateCreated":"2006-03-28","modifiedBy":"ONEDATA","dateModified":"2006-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3288504","version":"1","preferredName":"Negation Muscle Invasive Bladder Carcinoma","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:Muscle; one of the contractile organs of the body.:Marked by a tendency to spread especially into healthy tissue.:A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","longName":"C25594:C13056:C14159:C4912","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Muscle","conceptCode":"C13056","definition":"One of the contractile organs of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Invasive","conceptCode":"C14159","definition":"Marked by a tendency to spread, especially into healthy surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE8049FC-D50C-16F2-E040-BB89AD4341E8","latestVersionIndicator":"Yes","beginDate":"2011-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-04","modifiedBy":"ONEDATA","dateModified":"2011-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE8049FC-D51D-16F2-E040-BB89AD4341E8","latestVersionIndicator":"Yes","beginDate":"2011-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by T.Lichtenberg. mc 10/5/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3436269","version":"1","preferredName":"Bladder Cancer Treatment Type","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"3436269v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No treatment","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5569E4-4BBD-F494-E040-BB89AD432C65","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"ONEDATA","dateModified":"2012-04-10","deletedIndicator":"No"},{"value":"Bacillus Calmette-Guerin (BCG)","valueDescription":"BCG Solution","ValueMeaning":{"publicId":"3436270","version":"1","preferredName":"BCG Solution","longName":"3436270","preferredDefinition":"A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Solution","conceptCode":"C83496","definition":"A solution containing an attenuated, live culture preparation of the Bacillus Calmette Guerin (BCG) strain of Mycobacterium bovis with potential immunostimulating activity. Although the precise mechanism of action is unknown, upon intravesical administration, attenuated, live BCG bacteria in the solution come into direct contact with the bladder wall, inciting an antitumor granulomatous inflammatory reaction.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5569E4-4BC9-F494-E040-BB89AD432C65","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5569E4-4BE2-F494-E040-BB89AD432C65","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"ONEDATA","dateModified":"2012-04-10","deletedIndicator":"No"},{"value":"Transurethral resection alone","valueDescription":"Single Transurethral Resection","ValueMeaning":{"publicId":"3436271","version":"1","preferredName":"Single Transurethral Resection","longName":"3436271","preferredDefinition":"Not accompanied by another or others; exclusive of anyone or anything else. : (TRANZ-yoo-REE-thral ree-SEK-shun) Surgery performed with a special instrument inserted through the urethra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transurethral Resection","conceptCode":"C15705","definition":"Surgery performed with a special instrument inserted through the urethra.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5569E4-4BEF-F494-E040-BB89AD432C65","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5569E4-4C08-F494-E040-BB89AD432C65","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"ONEDATA","dateModified":"2012-04-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3436268","version":"1","preferredName":"Bladder Carcinoma Therapeutic Procedure Type","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4912:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5569E4-4B8C-F494-E040-BB89AD432C65","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"ONEDATA","dateModified":"2012-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5569E4-4B9D-F494-E040-BB89AD432C65","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"COOPERM","dateModified":"2012-04-13","changeDescription":"Released for TCGA per approval by T.Lichtenberg. mc 4/13/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"}]}],"AlternateNames":[{"name":"non_mibc_tx","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"If the patient does have a hi","type":"Preferred Question Text","description":"If the patient does have a history of non-muscle invasive bladder cancer, how was the patient treated?","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD571DAE-EC88-3EDD-E040-BB89AD43644D","latestVersionIndicator":"Yes","beginDate":"2012-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-10","modifiedBy":"TSESU","dateModified":"2018-07-16","changeDescription":"Released for TCGA per approval by T.Lichtenberg. mc 4/13/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}